CME online

in association with the 20th Annual World Congress on Insulin Resistance
Diabetes and Cardiovascular Disease -WCIRDC

CKD and Heart Failure – The New Epidemic

This is a CME Symposium Supported by an Educational Grant from AstraZeneca
Provided By:

Administrated by::
This CME online educational activity is approved for a maximum of 1.75 AMA PRA Category 2 Credit(s). and ABIM MOC

Accreditation period: January 15, 2022 – January 15, 2023

To get started:

Login / Register
CME information
View Agenda
Course presentation

To Receive a Certificate for This CME Activity:  

View the presentations in this CME activity and complete the evaluation. Your certificate will be mailed to you upon satisfactory completion of these documents.

CKD and Heart Failure – The New Epidemic
Agenda

Introduction & Pre-CME Questions
Yehuda Handelsman, MD

Epidemiology of HF & CKD in the General Population
Ralph DeFronzo, MD

Guideline Directed Management of Heart Failure
Biykem Bozkurt, MD, PhD

State of the Art Management of CKD
Robert Toto, MD

The Intersection of CKD and HF
Stephen Greene, MD

Panel Discussion - CKD and HF the Chicken and the Egg
Case Presentation: Yehuda Handelsman, MD
Panel: Ralph DeFronzo, MD • Stephen Greene, MD • Robert Toto, MD Biykem Bozkurt, MD, PhD Moderator: Yehuda Handelsman, MD

Faculty

Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE

Medical Director & Principal Investigator
The Metabolic Institute of America
Chair & Program Director
World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) / Heart in Diabetes (HID)
Chair & Founder
International Committee for Insulin Resistance
Tarzana, California

Ralph A. DeFronzo, MD

Professor of Medicine Chief
Diabetes Division
University of Texas Health Science Center at San Antonio
San Antonio, Texas


Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA

Mary and Gordon Cain Chair and Professor of Medicine Associate Provost of Faculty Affairs Senior Associate Dean of Faculty Development Senior Associate Editor for Circulation AHA/ASA Journals
Editor-in-Chief of Journal of the American College of Cardiology
Baylor College of Medicine
Houston, Texas

Robert D. Toto, MD

Professor of Internal Medicine
Associate Dean Translational Science and Education
University of Texas Southwestern Medical Center
Dallas, Texas

Stephen Greene, MD, FACC

Assistant Professor, Division of Cardiology
Advanced Heart Failure & Transplantation
Duke University Medical Center
Duke Clinical Research Institute
Durham, North Carolina

Program Description

Recent cardiovascular outcome trials (CVOTs) have demonstrated prevention of ASCVD, HF & CKD in patients with and without diabetes. Of note sodium glucose cotransporter 2 (SGLT2) inhibitors and antiplatelet agents. The management of patients with HF & CKD is often limited by hyperkalemia which must be addressed when implementing therapy for the patient with multiple cardiorenal and metabolic conditions. Some therapies like SGLT2i have the potential to lower hyperkalemia however at times potassium binders are required.

In this CME satellite symposium, through a patient case, we will explore the complex challenges of treating patients with CKD, heart failure, and/or type 2 diabetes (T2D) who also have or are at risk for ASCVD. Specifically we'll address clinicians’ gaps in knowledge of the interconnections between CKD, ASCVD, heart failure, and T2D and the required comprehensive management of these conditions when presented in the same patient.




Learning Objectives

Upon completion of this CME symposium, participants should be able to:

  • Discuss the epidemiology of HF and CKD
  • Describe the evidence supporting treatment recommendations for HF and CKD
  • Compare and contrast the benefits and limitations of established and emerging treatments for both HF and CKD based on outcome trial evidence
  • Develop management strategies for patients with complicated disease, including those with CKD and heart failure
  • Target Audience

    This educational initiative is designed for cardiologists, nephrologists, endocrinologists, internists, family physicians, and other healthcare professionals interested in the epidemiology, pathophysiology, prevention, and treatment of CKD and HF and prevention of morbidity and mortality.

    CME Statement

    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PES Inc. is accredited by the ACCME to provide continuing medical education for physicians.

    PESI, Inc, designated this live educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s).
    Physicians should only claim credit commensurate with the extent of their participation in the activity.